Skip to main content
Sun Pharmaceutical Industries Ltd. logo

Sun Pharmaceutical Industries Ltd. — Investor Relations & Filings

Ticker · SUNPHARMA ISIN · INE044A01036 LEI · 335800KJ7GE29LB4SS73 BSE.NS Manufacturing
Open in API
Filings indexed 1,411 across all filing types
Latest filing 2025-07-31 Call Transcript
Country IN India
Listing BSE.NS SUNPHARMA

About Sun Pharmaceutical Industries Ltd.

https://sunpharma.com/

Sun Pharmaceutical Industries Ltd. is a global leader in specialty generic pharmaceuticals, focused on developing, manufacturing, and marketing a comprehensive range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company’s extensive portfolio covers diverse therapeutic segments, including cardiology, psychiatry, neurology, gastroenterology, ophthalmology, dermatology, and orthopedics. It provides high-quality, affordable medicines across more than 100 markets worldwide, serving both chronic and acute care needs. A significant emphasis is placed on research and development to produce complex generics and innovative specialty products. The organization maintains a robust global manufacturing footprint, operating facilities that comply with stringent international regulatory standards. Its offerings encompass generics, branded generics, specialty medications, and over-the-counter products, aimed at improving patient outcomes globally.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 70% confidence The document is a short notice dated 31 July 2025 from Sun Pharmaceutical Industries Limited addressed to stock exchanges. It references Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements, 2015, and informs about the availability of the audio recording of an earnings call held on the same day. The document provides a link to the audio recording but does not contain the transcript or detailed financial data. The document length is only 1276 characters, indicating it is a brief announcement rather than a full transcript or report. According to the classification rules, announcements about availability of call recordings or links to them are classified as Call Transcript (CT) if they contain the full transcript, but since this is only a notice about the recording availability and not the transcript itself, it is best classified as a Regulatory Filing (RNS) as a general regulatory announcement. However, given the filing definitions, the closest specific category is Call Transcript (CT) because the subject is the earnings call audio recording. The document is not the transcript but an announcement about it. The rules specify that the transcript itself is CT, but announcements about availability of recordings are not explicitly defined. Given the content and context, the best fit is Call Transcript (CT) with moderate confidence, as it relates directly to the earnings call audio recording.
2025-07-31 English
Shareholders meeting
AGM Information Classification · 95% confidence The document is dated 31 July 2025 and is titled as the "Outcome of the 33rd Annual General Meeting (AGM)" of Sun Pharmaceutical Industries Limited. It includes a summary of the proceedings of the AGM, details of resolutions passed, and the Chairman's speech delivered at the AGM. The content focuses on the meeting's conduct, voting results, and speeches rather than presenting full financial statements or detailed financial analysis. The document length is 11,375 characters, which is substantial but the content is clearly about the AGM event and its outcomes, not the full annual report or financial statements. The presence of voting results, summary of proceedings, and Chairman's speech aligns with the definition of AGM Information (AGM-R). Therefore, the document should be classified as AGM Information (AGM-R).
2025-07-31 English
Outcome of Board Meeting
Regulatory Filings
2025-07-31 English
Updates
Legal Proceedings Report Classification · 95% confidence The document is an announcement regarding the execution of a settlement agreement related to a legal matter (In re Generic Pharmaceuticals Pricing Antitrust Litigation). It details the settlement terms, payment amount, and conditions, and is signed by the Company Secretary. There are no financial statements, earnings data, or detailed management discussion. The content is focused on legal proceedings and settlement information, which fits the category of Legal Proceedings Report (LTR). The document length is short and it is not a report publication announcement or certification. Therefore, the appropriate classification is LTR with high confidence.
2025-07-24 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated 21 July 2025 from Sun Pharmaceutical Industries Limited announcing top-line results from Phase 3 clinical studies evaluating a drug (tildrakizumab 100 mg, ILUMYA) for active psoriatic arthritis. It includes study details, safety information, and background on the drug and disease. The document is a formal announcement of clinical trial results and does not contain financial statements, management discussion, or regulatory filings related to financial performance. It is not an earnings release, annual report, or interim report. It is also not related to board changes, voting results, mergers, or share transactions. The document is a press release under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which is a regulatory announcement category. Therefore, the best fitting classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-07-21 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding newspaper advertisements about a special window for re-lodgement of transfer deeds of physical shares. It includes details about the SEBI circular, the special window period, and instructions for investors. The document is a formal announcement informing the market and shareholders about this regulatory update and the publication of newspaper advertisements. It does not contain financial statements, audit information, management discussion, or any detailed report content. The document is approximately 15,000 characters but is essentially an announcement of a regulatory or compliance matter related to share transfer procedures. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-07-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.